Supernus Pharmaceuticals Files Q1 2025 10-Q
Ticker: SUPN · Form: 10-Q · Filed: 2025-05-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: SUPN
TL;DR
SUPN Q1 2025 10-Q is in. Check financials.
AI Summary
Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results for the first quarter of 2025. Key financial data and operational updates are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Supernus Pharmaceuticals, Inc., crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Supernus is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the beginning of the fiscal quarter for which financial information is reported.)
- 2024-12-31 — Prior Fiscal Year End Date (Provides a point of comparison for financial performance.)
Key Players & Entities
- SUPERNUS PHARMACEUTICALS, INC. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250506 (date) — Filing Date
- 2834 (other) — Standard Industrial Classification Code
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 6, 2025.
What is Supernus Pharmaceuticals, Inc.'s Standard Industrial Classification code?
Supernus Pharmaceuticals, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end date?
The company's fiscal year end date is December 31.
What are the key dates associated with the reporting period?
The reporting period starts on January 1, 2025, and ends on March 31, 2025.
From the Filing
0001356576-25-000033.txt : 20250506 0001356576-25-000033.hdr.sgml : 20250506 20250506162044 ACCESSION NUMBER: 0001356576-25-000033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 25917571 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-Q 1 supn-20250331.htm 10-Q supn-20250331 0001356576 false 12-31 2025 Q1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent 730 xbrli:shares iso4217:USD iso4217:USD xbrli:shares supn:product supn:segment xbrli:pure supn:right iso4217:EUR 0001356576 2025-01-01 2025-03-31 0001356576 2025-04-29 0001356576 2025-03-31 0001356576 2024-12-31 0001356576 us-gaap:ProductMember 2025-01-01 2025-03-31 0001356576 us-gaap:ProductMember 2024-01-01 2024-03-31 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2025-01-01 2025-03-31 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2024-01-01 2024-03-31 0001356576 2024-01-01 2024-03-31 0001356576 us-gaap:CommonStockMember 2024-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001356576 us-gaap:RetainedEarningsMember 2024-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001356576 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001356576 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001356576 us-gaap:CommonStockMember 2025-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001356576 us-gaap:RetainedEarningsMember 2025-03-31 0001356576 us-gaap:CommonStockMember 2023-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001356576 us-gaap:RetainedEarningsMember 2023-12-31 0001356576 2023-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001356576 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001356576 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001356576 us-gaap:CommonStockMember 2024-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001356576 us-gaap:RetainedEarningsMember 2024-03-31 0001356576 2024-03-31 0001356576 supn:QelbreeMember 2025-01-01 2025-03-31 0001356576 supn:QelbreeMember 2024-01-01 2024-03-31 0001356576 supn:GOCOVRIMember 2025-01-01 2025-03-31 0001356576 supn:GOCOVRIMember 2024-01-01 2024-03-31 0001356576 supn:APOKYNMember 2025-01-01 2025-03-31 0001356576 supn:APOKYNMember 2024-01-01 2